Pharma's Big Defeat: US Rebate Proposal Hits The End Of The Road
White House will not move forward with a rebate proposal the drug industry supported as a way to lower patient drug spending.
You may also be interested in...
Over the past 20 years, the pharmaceutical industry has notched a series of wins with its extraordinary federal lobbying expenditures and campaign contributions. A new JAMA Internal Medicine study examines spending from 1999-2018.
A new study looks at list drug price increases and manufacturer discounts over 11 years and finds that despite significant rebates, net price increases still grew 3.5 times more than inflation.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.